NEW YORK (GenomeWeb) – Avant Diagnostics and Amarantus Diagnostics this week signed a letter of intent to acquire clinical proteomics firm Theranostics Health as part of the two firms' planned merger.

The deal, which is expected to close by the end of March, brings together three companies that have to date struggled to ramp their molecular testing businesses in hopes that the combined outfit will be better positioned to succeed in the market, suggested Gerald Commissiong, president and CEO of Amarantus Bioscience, the parent firm of Amarantus Diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.